Compare PNTG & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PNTG | TYRA |
|---|---|---|
| Founded | 2019 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 841.6M | 844.2M |
| IPO Year | N/A | 2021 |
| Metric | PNTG | TYRA |
|---|---|---|
| Price | $28.94 | $22.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $35.33 | $31.20 |
| AVG Volume (30 Days) | 299.1K | ★ 462.3K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.47 | N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $847,274,000.00 | N/A |
| Revenue This Year | $36.69 | N/A |
| Revenue Next Year | $24.06 | N/A |
| P/E Ratio | $38.32 | ★ N/A |
| Revenue Growth | ★ 29.89 | N/A |
| 52 Week Low | $21.18 | $6.42 |
| 52 Week High | $31.57 | $22.83 |
| Indicator | PNTG | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 65.94 | 72.42 |
| Support Level | $28.61 | $20.08 |
| Resistance Level | $30.26 | $22.83 |
| Average True Range (ATR) | 0.97 | 1.60 |
| MACD | 0.27 | 0.20 |
| Stochastic Oscillator | 72.59 | 89.04 |
Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.